TY  - JOUR
AU  - Weiss, Lena
AU  - Heinemann, Volker
AU  - Fischer, Laura E
AU  - Gieseler, Frank
AU  - Hoehler, Thomas
AU  - Mayerle, Julia
AU  - Quietzsch, Detlef
AU  - Reinacher-Schick, Anke
AU  - Schenk, Michael
AU  - Seipelt, Gernot
AU  - Siveke, Jens
AU  - Stahl, Michael
AU  - Vehling-Kaiser, Ursula
AU  - Waldschmidt, Dirk T
AU  - Dorman, Klara
AU  - Zhang, Danmei
AU  - Westphalen, C Benedikt
AU  - von Bergwelt-Baildon, Michael
AU  - Boeck, Stefan
AU  - Haas, Michael
TI  - Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
JO  - Clinical and translational oncology
VL  - 26
IS  - 5
SN  - 1699-048X
CY  - Mailand
PB  - Springer Milan
M1  - DKFZ-2023-02012
SP  - 1268-1272
PY  - 2024
N1  - 2024 May;26(5):1268-1272
AB  - To analyze the 3-month life expectancy rate in pancreatic cancer (PC) patients treated within prospective trials from the German AIO study group.A pooled analysis was conducted for patients with advanced PC that were treated within five phase II/III studies conducted between 1997 and 2017 (Gem/Cis, Ro96, RC57, ACCEPT, RASH). The primary goal for the current report was to identify the actual 3-month survival rate, a standard inclusion criterion in oncology trials.Overall, 912 patients were included, 83
KW  - Clinical trial (Other)
KW  - Inclusion criterion (Other)
KW  - Pancreatic cancer (Other)
KW  - Prognosis (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37794220
DO  - DOI:10.1007/s12094-023-03323-1
UR  - https://inrepo02.dkfz.de/record/284423
ER  -